ARCHIVES

Slow Accruing Trials Should Be Removed From High Priority Program, Broder Says

This article is from The Cancer Letter archive.

Vol. 18 No. 38 | October 2, 1992

Download PDF Visit The Full Archive

Related Articles

In Brief: FDA Oncological Drugs Advisory Committee Gets New Charter, Georgetown’s Schein Is Chairman

October 13, 1978

NCI Puts $36 Million In Stimulus Funds Towards Early Clinical Trials

September 4, 2009

FDA Approves Xtandi For Late-Stage Castration-Resistant Prostate Cancer

August 31, 2012

Risk of Lymphoma Increases with Hepatitis C Virus Infection

May 25, 2007

Patient Care Emerges as Major Concern Following Sequestration Cuts to Medicare

April 5, 2013

2018 State of Cancer Care in America

February 3, 2022